Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Anika Therapeutics (NASDAQ: ANIK) granted restricted stock units covering 3,360 common shares to a newly hired non-executive employee, effective June 1, 2026.
Rhea-AI Summary
Anika Therapeutics (NASDAQ: ANIK) granted restricted stock units covering 3,360 common shares to a newly hired non-executive employee, effective June 1, 2026.
The award, issued under the 2021 Inducement Plan and Nasdaq Listing Rule 5635(c)(4), vests in three equal annual installments over three years, contingent on continuous service.
Positive
- None.
Negative
- None.
Details
News Market Reaction – ANIK
In the Jun 8 session, ANIK gained 0.83%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- RSU grant size
- 3,360 shares
- Inducement grant to one newly hired non-executive employee on June 1, 2026
- Vesting schedule
- 3 equal installments
- RSUs vest on each of the first three anniversaries of grant date
- Plan year
- 2021 Inducement Plan
- Equity granted under Anika Therapeutics, Inc. 2021 Inducement Plan, as amended
Historical Context
-
Reported Q1 revenue growth, margin expansion, positive adjusted EBITDA, and reaffirmed guidance.
-
Announced timing and access details for upcoming Q1 2026 earnings release and call.
-
Granted 3,138 RSUs to a new employee under Nasdaq inducement rules.
-
Reported Q4 margin expansion, cash generation, 2026 guidance, and ongoing repurchase program.
-
Announced CEO presentation and investor meetings at a musculoskeletal conference.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
restricted stock units financial
nasdaq listing rule 5635(c)(4) regulatory
equity award financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
BEDFORD, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in the osteoarthritis pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced that on June 1, 2026, Anika granted restricted stock units (“RSUs”) covering an aggregate of 3,360 shares of common stock to one newly hired non-executive employee. The grant was made pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, was approved by the compensation committee of the board of directors pursuant to a delegation of authority by the board of directors, and, in accordance with Nasdaq Listing Rule 5635(c)(4), was made as a material inducement to the grantee’s acceptance of employment with Anika as a component of the grantee’s employment compensation.
The RSUs will vest in three equal installments on each of the first three anniversaries of the grant date, in each case for so long as the grantee provides continuous service to Anika through the relevant vesting date.
The RSUs are subject to the terms and conditions of the equity award agreement approved by Anika. The RSUs were granted pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, which was not subject to stockholder approval.
About Anika
Anika Therapeutics, Inc. (NASDAQ: ANIK), is the global leader in the design, development, manufacturing, and commercialization of hyaluronic acid innovations. In partnership with clinicians, our sole focus is dedicated to delivering and advancing osteoarthritis pain management and orthopedic regenerative solutions. At our core is a passion to deliver a differentiated portfolio that improves patient outcomes around the world. Anika’s global operations are headquartered outside of Boston, Massachusetts. For more information about Anika, please visit www.anika.com.
For Investor Inquiries:
Anika Therapeutics, Inc.
Matt Hall, 781-457-9554
Director, Corporate Development and Investor Relations
investorrelations@anika.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.